697 Burke Road
Suite 201
Camberwell, VIC 3124
Australia
61 3 9092 0480
https://www.neurenpharma.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein:
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. | CEO, MD & Executive Director | 1,07M | S.O. | S.O. |
Ms. Lauren Frazer C.A. | CFO & Company Secretary | S.O. | S.O. | S.O. |
Mr. Lawrence Glass BA (Biology) | Chief Science Officer | S.O. | S.O. | S.O. |
Mr. Gerry Zhao | Vice President of Corporate Development | S.O. | S.O. | S.O. |
Dr. Liza A. Squires M.D. | Chief Medical Officer | S.O. | S.O. | S.O. |
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
L’ISS Governance QualityScore de Neuren Pharmaceuticals Limited en date du 1 mai 2024 est 7. Les scores principaux sont Audit : 9; Société : 7; Droits des actionnaires : 1; Compensation : 5.